Department of Epidemiology & State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China;School of Public Health, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Department of Epidemiology & State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China;School of Public Health, Fudan University, Shanghai 200025, China.
Biomed Environ Sci. 2024 Aug 20;37(8):897-921. doi: 10.3967/bes2024.133.
Gynecological cancer significantly affect the health of women. This review aimed to describe the global patterns and trends in the survival of patients with gynecological cancers. We searched PubMed, Embase, Web of Science, SinoMed, and SEER for survival analyses of cancer registration data of cervical, endometrial, and ovarian cancers published between 1980 and 2022. Globally, the highest 5-year observed survival rate for cervical cancer was 76.5% in Anshan, Liaoning, China (2008-2017). The 5-year observed survival rates of endometrial and ovarian cancers were higher in Finland (1995-1999, 82.5%) and Singapore (1988-1992, 62.0%). The 5-year relative survival rate of cervical cancer patients was higher in Haining, Zhejiang, China (2011-2014, 85.8%). Korea ranked first at 89.0% and 64.5% for endometrial and ovarian cancers, respectively. Survival rates have improved for cervical, endometrial, and ovarian cancers. Patients aged ≥ 75 years and those with advanced-stage disease had the worst 5-year survival rates. Survival rates were better for squamous cell carcinoma in cervical cancer, for endometrial carcinoma and mucinous adenocarcinoma in endometrial cancer, and for germ cell and sex-cord stromal tumors in ovarian cancer. Over the past four decades, the survival rates of gynecological cancers have increased globally, with notable increases in cervical and endometrial cancers. Survival rates are higher in developed countries, with a slow-growing trend. Future studies should focus on improving survival, especially in ovarian cancer patients.
妇科癌症严重影响女性健康。本综述旨在描述全球妇科癌症患者生存状况的模式和趋势。我们检索了 PubMed、Embase、Web of Science、SinoMed 和 SEER 中发表于 1980 年至 2022 年的癌症登记数据生存分析,以评估宫颈癌、子宫内膜癌和卵巢癌的生存情况。全球范围内,中国辽宁鞍山(2008-2017 年)宫颈癌的 5 年观察生存率最高,为 76.5%。芬兰(1995-1999 年)和新加坡(1988-1992 年)子宫内膜癌和卵巢癌的 5 年观察生存率较高,分别为 82.5%和 62.0%。中国浙江海宁(2011-2014 年)宫颈癌患者的 5 年相对生存率最高,为 85.8%。韩国在宫颈癌和卵巢癌的 5 年相对生存率方面分别排名第一,为 89.0%和 64.5%。宫颈癌、子宫内膜癌和卵巢癌的生存率均有所提高。年龄≥75 岁和晚期疾病患者的 5 年生存率最差。宫颈癌中鳞癌、子宫内膜癌中子宫内膜癌和黏液性腺癌、卵巢癌中生殖细胞癌和性索间质肿瘤的生存率较好。在过去的四十年中,全球范围内妇科癌症的生存率有所提高,宫颈癌和子宫内膜癌的生存率显著提高。在发达国家,生存率较高,且呈缓慢增长趋势。未来的研究应重点关注提高生存率,特别是在卵巢癌患者中。